I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理层变动、收购传闻、退市风险

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low.
抗癌药研发公司天境生物最近频繁出现在一系列影响市场的头条新闻中，尽管股票仍接近历史最低点。

咏竹坊

更新于2022年5月9日 14:05 咏竹坊

There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose stock is getting pulled every which way as a result.

作者刘小燕本文仅代表作者个人观点

您已阅读2%（183字），剩余98%（8291字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。

咏竹坊

咏竹坊（官网链接）提供在香港和美国上市的manbetx3.0 企业相关新闻，重点关注中小企业和筹备上市的公司。

Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理层变动、收购传闻、退市风险

咏竹坊

制药业

相关话题

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat天境生物巨震：管理层变动、收购传闻、退市风险

咏竹坊

制药业

相关话题

推荐阅读

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理层变动、收购传闻、退市风险